A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ABOUT PFIZER Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of Pfizer Inc.2025 Form 10-K biopharmaceutical products worldwide. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. The Company was incorporated under the laws of the State of Delaware on June 2, 1942. Most of our revenues come from the manufacture and sale of biopharmaceutical products.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 62.6B | 62.6B | 63.6B | 59.6B | 100.3B | 81.3B |
| Net Income | 7.8B | 7.8B | 8.0B | 2.1B | 31.4B | 22.0B |
| EPS | $1.36 | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 |
| Free Cash Flow | 9.1B | 9.1B | 9.8B | 4.8B | 26.0B | 29.9B |
| ROIC | 6.9% | 7.3% | 8.1% | 2.0% | 29.3% | 26.9% |
| Gross Margin | 74.3% | 74.3% | 71.9% | 58.1% | 65.8% | 62.1% |
| Debt/Equity | 0.79 | 0.79 | 0.81 | 0.92 | 0.41 | 0.53 |
| Dividends/Share | $1.71 | $1.72 | $1.69 | $1.65 | $1.61 | $1.57 |
| Operating Income | 10.2B | 10.2B | 11.2B | 3.2B | 36.1B | 25.3B |
| Operating Margin | 16.4% | 16.4% | 17.6% | 5.4% | 36.0% | 31.1% |
| ROE | 9.0% | 8.9% | 9.1% | 2.4% | 32.8% | 28.5% |
| Shares Outstanding | 5,714M | 5,714M | 5,696M | 5,727M | 5,735M | 5,709M |
PFIZER INC passes 3 of 9 quality checks, indicating weak fundamentals.
PFIZER INC trades at 20.1x trailing earnings, compared to its 15-year median P/E of 16.9x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 17.1x vs a median of 13.2x. The company's 5-year average ROIC is 14.7% with a gross margin of 66.4%. Total shareholder yield (dividends) is 6.3%. At current prices, the estimated annualized return to fair value is -1.1%.
PFIZER INC (PFE) has a current P/E ratio of 20.1, compared to its historical median P/E of 16.9. The stock is currently considered Fair based on its historical valuation range.
PFIZER INC (PFE) has a 5-year average return on invested capital (ROIC) of 14.7%. This indicates solid capital allocation.
PFIZER INC (PFE) has a market capitalization of $156.2B. It is classified as a large-cap stock.
Yes, PFIZER INC (PFE) pays a dividend with a trailing twelve-month yield of 6.25%.
Based on historical P/E analysis, PFIZER INC (PFE) appears fair. The current P/E of 20.1 is 19% above its historical median of 16.9. The estimated fair value CAGR (P/E method) is -7.9%.
PFIZER INC (PFE) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
PFIZER INC (PFE) reported annual revenue of $62.6 billion in its most recent fiscal year, based on SEC EDGAR filings.
PFIZER INC (PFE) has a net profit margin of 12.4%. This is a healthy margin.
PFIZER INC (PFE) generated $9.1 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
PFIZER INC (PFE) has a debt-to-equity ratio of 0.79. This indicates moderate leverage.
PFIZER INC (PFE) reported earnings per share (EPS) of $1.36 in its most recent fiscal year.
PFIZER INC (PFE) has a return on equity (ROE) of 8.9%. This indicates moderate shareholder returns.
PFIZER INC (PFE) has a 5-year average gross margin of 66.4%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 19 years of financial data for PFIZER INC (PFE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PFIZER INC (PFE) has a book value per share of $15.13, based on its most recent annual SEC filing.